glp-1
(25)
The Fund That Runs the Warehouse Before It Writes the Check
Most food VCs write a check and wait. Siddhi Capital shows up with a supply-chain team - and a thesis that the next decade of consumer eating gets rewritten by weight-loss drugs.
The 176-Year-Old Startup That Sells Science by the Milligram
It began as a candy-flavored worm medicine in a Brooklyn brick house. Today Pfizer is racing to replace its Covid windfall with cancer drugs and weight-loss pills before the patents run out.
The Diet That Invented Group Therapy Now Writes Prescriptions
It taught a generation to count points and lean on each other. Then a weekly shot changed the math - so WeightWatchers went to the doctor.
Eli Lilly and Company
The company that mass-produced insulin now runs on a molecule that helps people lose weight. Inside the 150-year-old Indianapolis drugmaker that became a trillion-dollar bet on metabolism.
Berry Street
Berry Street is a New York-based digital health company that connects patients with registered dietitians for insurance-covered, virtual nutrition therapy while giving those dietitians an AI-enabled 'business-in-a-box' to run independent practices. Founded in 2023 by Noah Kotlove and Jesse Rose, the platform pairs a consumer marketplace - where most clients pay $0 out of pocket - with back-office tooling that handles insurance credentialing, claims, documentation and patient communication. It works with a network of more than 1,000 dietitians and 1,250-plus insurance plans, and raised a $50 million Series B in early 2025.
CORXEL Pharmaceuticals
CORXEL Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic diseases worldwide. Spun out of RTW Investments in 2019 (formerly JiXing Pharmaceuticals) and dual-based in Berkeley Heights, New Jersey and Shanghai, CORXEL is advancing a pipeline led by CX11, a differentiated oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, alongside JX10 for acute ischemic stroke and JX09 for hypertension. In January 2026 the company raised up to $287 million in Series D1 financing to push these programs through late-stage clinical trials.
Dandelion Health
Dandelion Health is a New York-based clinical AI and real-world data company that turns de-identified patient records from a network of U.S. hospitals into research-ready datasets and software for drug developers and AI teams. Its multimodal platform combines structured records, clinical notes, medical images, and raw biological signals such as ECG waveforms across roughly 15 million patients, helping pharmaceutical companies design smarter trials, discover biomarkers, generate real-world evidence, and validate healthcare algorithms against diverse populations.
Elliott Green
Elliott Green is the co-founder and CEO of Dandelion Health, a New York-based real-world data and clinical AI platform building multimodal, longitudinal datasets from a consortium of non-academic health systems. A former founding member of Oscar Health with a finance background, Green launched Dandelion in 2020 to give life science companies and AI developers unbiased, clinical-grade data - including the images, waveforms, and notes that make up most of medicine but are rarely used. The company closed a $14M Series A in 2026 and has launched a free AI validation service and a GLP-1 data library aimed at bringing precision medicine to cardiometabolic disease.
James O'Mara
James (Jim) O'Mara is the President and CEO of Neurogastrx, a Woburn, Massachusetts specialty pharmaceutical company developing oral therapies for gastrointestinal disorders. A pharmacist by training with decades in biotech, he was one of the original members of the LINZESS team at Ironwood Pharmaceuticals, where he rose to Senior Vice President of Corporate Development and drove licensing deals across the U.S., Europe, Japan and China. At Neurogastrx he raised a $60 million Series B and is steering the company's lead candidate, NG101, through clinical studies aimed at the nausea and vomiting that lead many patients to abandon GLP-1 weight-loss and diabetes medicines.
Noah Kotlove
Noah Kotlove is the co-founder and CEO of Berry Street, a New York-based telehealth platform that connects patients with insurance-covered registered dietitians and gives independent RDs the software to run their practices. He launched Berry Street in 2023 with Jesse Rose after his own experience with a dietitian led to sustained results where fad diets had not. Before Berry Street, Kotlove built Sobrietysoft, an addiction recovery app that grew to more than six million users, and worked as a senior innovation consultant at Accenture after graduating from Wharton. In February 2025 Berry Street raised a $50M Series B led by Northzone, with Sofina, FJ Labs, the founder of Revolut, the co-founders of Spring Health and Grow Therapy, and the CEO of Found also participating.
Sandy Mou
Sandy Mou, MD, is the Chief Executive Officer and Board Executive Director of CORXEL Pharmaceuticals, a New Jersey- and Shanghai-linked biotech developing an oral small molecule GLP-1 receptor agonist for obesity and diabetes. A Fudan-trained clinician turned pharma executive with nearly three decades at GSK, AstraZeneca, Johnson & Johnson, and MSD, she led MSD China's oncology unit into the country's top three within three years and later took Shanghai Allist public on the STAR Market before joining JIXING - now CORXEL - in early 2023.
Prado
Prado is an Austin-based Food-as-Medicine platform that lets clinicians prescribe medically tailored meals and lets patients pay for them with pre-tax HSA/FSA dollars. It stitches together the parts that usually don't talk to each other - a compliant Letter of Medical Necessity, HIPAA- and IRS-approved checkout, white-label storefronts, and fulfillment - so healthy prepared food becomes both prescribable and reimbursable. Founded in 2020 by former Snap Kitchen CEO Jon Carter, Prado has supported the sale of more than 25 million meals and connects food operators to a network of 70M+ tax-advantaged account holders.
Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company building the RaniPill, a swallowable robotic capsule that delivers injectable biologics - peptides, proteins and antibodies - orally, with dissolvable microneedles that painlessly inject the drug into the intestinal wall. Founded in 2012 out of Mir Imran's InCube Labs and now Nasdaq-listed (RANI), Rani aims to replace the needle for chronic conditions ranging from obesity and metabolic disease to immunology and rare disease.
Helicore Biopharma
Helicore Biopharma is a South San Francisco clinical-stage biopharmaceutical company building first-in-class GIP (glucose-dependent insulinotropic polypeptide) antagonists for obesity and cardiometabolic disease. Its lead candidate, HCR-188, is a humanized monoclonal antibody that binds circulating GIP ligand rather than the GIP receptor, a mechanism designed to improve the quality of weight loss - favoring fat loss over lean mass when paired with GLP-1 - and to restore leptin sensitivity. Incubated by Versant Ventures, the company emerged from stealth in January 2025 with a $65 million Series A and is advancing a pipeline of long-acting antibody-peptide conjugates aimed at quarterly dosing.
Virta Health
Virta Health is a digital health company on a mission to reverse type 2 diabetes and obesity in 100 million people. Founded in 2014 by Sami Inkinen, Dr. Stephen Phinney, and Dr. Jeff Volek, Virta pairs a nutrition-first, low-carbohydrate clinical protocol with a Continuous Remote Care platform - a mobile app, dedicated physicians and health coaches, and AI-driven personalization - to lower blood sugar, cut medications, and produce durable weight loss without relying on costly drugs or surgery. Sold to employers and health plans on a value-based, outcomes-guaranteed model, Virta has treated over 100,000 members and surpassed $160M in annualized revenue.
one.bio
one.bio is a Sacramento biotechnology company that releases short-chain plant fibers and makes them flavorless, odorless, colorless and water-soluble so they can be added to food and drinks at high doses without changing taste or texture. Spun out of UC Davis, it pairs a fiber-mapping knowledgebase called the Glycopedia with a proprietary depolymerization process to turn long-chain plant carbohydrates - including agricultural byproducts - into bioactive fibers that feed the microbiome and support metabolic and immune health. The company raised a $27M Series A in December 2024 and in early 2026 launched its discovery platform, its first clinically validated ingredient (one.bio 01) and a consumer brand, GoodVice.
Peter DiLaura
Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.
Hone Health
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.
Sesame
Sesame is a direct-pay, cash-only healthcare marketplace that lets patients shop for doctor visits, labs, imaging, prescriptions and specialty care online without insurance. Often called 'the Expedia for medical care,' it lists transparent prices from thousands of providers across all 50 states, with one-time visits starting around $39 and memberships from $19. Founded in 2018 by David Goldhill, Michael Botta and John Fontein, Sesame aims to strip bureaucracy out of healthcare so patients and clinicians transact directly.
Sami Inkinen
Sami Inkinen is a Finnish-born, Stanford-trained entrepreneur and the co-founder and CEO of Virta Health, a company on a mission to reverse metabolic disease in one billion people through nutrition, technology, and AI. He earlier co-founded the real estate marketplace Trulia, taking it public in 2012 before its merger with Zillow. A self-described 'incurable data geek' and world-class endurance athlete, he is a triathlon age-group world champion and, in 2014, rowed 2,750 miles unsupported across the Pacific from California to Hawaii with his wife in a record-setting 45 days to raise awareness about sugar and metabolic disease.
GoodRx
GoodRx is a Santa Monica-based digital healthcare platform that helps Americans find lower prices on prescription drugs. It aggregates real-time pricing and discounts from pharmacies nationwide so consumers can compare costs and access free coupons, then layers on telehealth visits, manufacturer savings programs, and tools for pharma and employers. Since 2011 it has helped tens of millions of people save an estimated $70+ billion on medications.
Omada Health
Omada Health is a publicly traded (Nasdaq: OMDA) virtual chronic care company that uses behavioral science, connected devices, AI tools, and human care teams to help people manage prediabetes, diabetes, hypertension, high cholesterol, musculoskeletal conditions, and weight - including support for members on GLP-1 medications. Founded in 2011 in San Francisco, it sells to employers, health plans, and pharmacy benefit managers, serving roughly 2,000-plus customers and more than 886,000 members.
Vida Health
Vida Health is a San Francisco-based digital health company that pairs an AI-powered, personalized app with human coaches, dietitians, therapists, and physicians to prevent, manage, and reverse chronic physical and mental conditions. Its virtual cardiometabolic clinic treats obesity, diabetes, hypertension, and the depression and anxiety that travel with them, and is sold to employers and health plans as a clinically validated, cost-managed alternative to fragmented point solutions, including responsible GLP-1 prescribing.
Joe Murad
Joe Murad is President and CEO of Vida Health, a San Francisco-based virtual care company. A two-decade healthcare technology operator, he previously ran WithMe Health and PokitDok (acquired by Change Healthcare), with earlier leadership roles at Willis Towers Watson, Extend Health, and eHealth.
Lark Health
Lark Health is a Mountain View-based digital health company that delivers 24/7, AI-powered nurse coaching for chronic conditions - diabetes, hypertension, weight, behavioral health and tobacco cessation - through a text-message-style app paired with connected devices. Built on cognitive behavioral therapy and used by major payers, Lark scales personalized care to tens of millions of covered lives.